NCT06352892View on ClinicalTrials.gov

A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

April 25, 2024

Primary Completion Date

August 27, 2024

Study Completion Date

August 27, 2024

Conditions

Obesity

Interventions

DRUG

Maridebart Cafraglutide

Solution for SC injection.

Trial Locations (1)

000

Queen Mary Hospital, Hong Kong

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY

NCT06352892 - A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight | Biotech Hunter | Biotech Hunter